Advertisement: Wild Knight Vodka
Advertisement: HCR Hewitsons mid banner
Advertisement: SATAVIA mid banner
Advertisement: Cambridge Network mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: S-Tech mid banner 3
Advertisement: Bar Ellison mid banner property
Advertisement: RSM mid banner
Advertisement: partnersand mid banner
ARM Innovation Hub
Mid banner advertisement: BDO
Advertisement: Simpsons Creative
Barr Ellison Solicitors – commercial property
Advertisement: EBCam mid banner
Advertisement: CJBS mid banner
Cambridgeand mid banner advertisement
Advertisement: Mogrify mid banner
Advertisement: TTP
Advertisement: Kao Data Centre mid banner
25 October, 2019 - 07:52 By Kate Sweeney

Cambridge molecular assay start-up wins £500k from Innovate UK

Cambridge startup Biofidelity Ltd, which is providing advanced molecular assays for the sensitive detection of low-frequency genetic mutations, has won £500,000 in grant funding from Innovate UK. 

Together with its £750,000 seed financing, announced earlier this month, the Innovate UK grant brings the total amount to date raised by Biofidelity to £1.25 million.

The grant will enable Biofidelity to explore applications of its novel chemistry platform for oncology patient monitoring with samples taken directly from patient blood.

The money has been channelled through Innovate UK’s ‘Innovation in Precision Medicine Investment Accelerator’ and will support the development of Biofidelity’s novel chemistry platform for ultra-sensitive, affordable detection of gene targets, enabling better targeting of therapies and monitoring of their effectiveness.

The grant will co-fund a 12-month project to validate the chemistry for sensitive detection of mutations used to guide treatment of non-small-cell lung cancer, including acquired mutations which confer resistance to common therapies.

Biofidelity will develop its platform chemistry for use in companion diagnostic tests. Such tests help guide therapy, providing vital information on potential efficacy while enabling monitoring of the acquisition of resistance. 

Resistance monitoring is critical and indicates when a patient should be switched to an alternative therapy. This can be useful during treatment with cancer drugs, as tumours will often develop mutations which confer resistance to the therapy.

Genomics-based diagnostic tests are generally tissue-based, requiring an invasive, costly and potentially high-risk procedure to obtain a sample from the patient.

Non-invasive testing (or ‘liquid biopsy’), which uses analysis of circulating cell-free DNA in the blood, is an alternative which holds great promise as a method of routine screening.

However, a typical liquid biopsy sample may contain as little as a single target DNA molecule, often differing from healthy DNA by only a single point mutation. As a result, a very high level of specificity is required to avoid false positives.

Biofidelity’s proprietary platform uses a novel set of biochemical reactions and an easily adopted workflow to enable target DNA sequences to be detected and protected while irrelevant DNA is removed.

The extreme sensitivity and specificity of Biofidelity’s assays also enables the detection of genetic mutations or target genes at a much earlier stage, allowing earlier intervention with targeted treatment.

The chemistry can also be multiplexed to enable simultaneous detection of large panels of DNA mutations at extremely low frequencies, making it suitable for use for a broad range of cancers. 

CEO Dr Barnaby Balmforth said: “Our aim is to improve patient outcomes by providing easily adopted advanced molecular assays that dramatically increase the speed and effectiveness of diagnosis. 

“Our platform chemistry could enable precision medicine across a broad range of therapies, with samples taken from either blood or tissue, meaning both routine screening and patient monitoring become far more cost effective and less intrusive. 

“The funding from Innovate UK will accelerate the rate at which we can successfully implement the technology for effective targeting of therapies.”
Discuss this document

Newsletter Subscription

Stay informed of the latest news and features